Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. New Zealand
  4. New Zealand Stock Exchange
  5. AFT Pharmaceuticals Limited
  6. News
  7. Summary
    AFT   NZAFTE0001S4


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

AFT Pharmaceuticals : 24-hour efficacy for Crystawash Extend Hand SanitiserOpens in a new Window

01/18/2021 | 12:10am EDT

Market and media release

11 January 2021

AFT confirms demonstration of 24-hour efficacy for

Crystawash Extend Hand Sanitiser

AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces independent laboratories have found that its new Crystawash Extend Hand Sanitiser:

  • Displays 24-hour residual efficacy against germs evidenced by testing on synthetic skin1 against S.Aureus and E.Coli2
  • Kills 99.99% of germs on immediate contact being S.Aureus, E.Coli, P.aeruginosa, and E. hirae3
  • Meets the accepted standard for killing Corona virus, evidenced by activity against the Corona virus surrogate [Murine hepatitis virus (MHV1)4

The newly developed, ethanol free, foaming formulation adds to AFT's existing Crystawash sanitiser range in Australia and New Zealand and meets the huge demand for hand sanitiser that has emerged with the Covid-19 pandemic. It also enhances the appeal of AFT's over-the-counter portfolio of medicines, now sold in more than 6,000 pharmacies and other outlets across Australasia.

AFT Managing Director Dr Hartley Atkinson said: "Crystawash Extend's long-lasting protection offers real advantages over many other sanitisers, which are challenged every time a new surface is touched.

"Crystawash Extend covers the hands with an invisible, water-proof, biostatic layer that ruptures the membranes of germs upon contact. The result is effective hand sanitisation and protection against contact of multiple germ-infected surfaces. The chosen formulation was developed after rigorous testing on a number of potential formulations"

Dr Atkinson said AFT believes the product has long-term potential.

"Despite the very welcome advent of several COVID-19 vaccines, we see no let-up in demand for effective hand sanitiser. The vaccination programme will take some time to roll out. And even after the programme has been completed, we expect consumer interest in hand sanitisation to remain strong."

Dr Atkinson said Crystawash Extend sales will add to this financial year's results in Australia and New Zealand and also has potential around the world as AFT leverages its global network of partners to out-license the product in other jurisdictions. Already Canada's CombomedPharma Inc has agreed to distribute Crystawash Extend in that country and more agreements are expected to follow.

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand

Incorporated in New Zealand ARBN: ARBN 609 017 969 investor.relations@aftpharm.com


  1. VITRO-SKIN®;Florida Suncare Testing, Inc. IMS Division. https://ims-usa.com/vitro-skin- substrates/vitro-skin/
  2. AFT Pharmaceuticals/AsureQuality Laboratory Services, New Zealand microbiological effectiveness study evaluating residual killing activity against transient microbial skin flora on synthetic skin (test organisms: S.Aureus NZRM 147/ATCC 6538 and E.Coli NZRM 2577/ATCC 8739).
  3. Time Kill Test conducted by Eurofins BioPharma Product Testing, Australia; Protocol: TMD-110, EN
    13727; Test organisms: S.Aureus ATCC 6538, E.Coli NCTC 10538, P.aeruginosa ATCC 15442, and E. hirae ATCC 10541
  4. Virucidal Test by Carrier Method conducted by Eurofins BioPharma Product Testing, Australia; Protocol: TMCV 006, ASTM E1053; Test organisms: Murine hepatitis virus (MHV1) ATCC/VR-261.

For more information:



Dr Hartley Atkinson

Richard Inder

Managing Director

The Project

AFT Pharmaceuticals

Tel: +64 21 645 643

Tel: +64 9488 0232

About AFT Pharmaceuticals

AFT is a growing multinational pharmaceutical business with a broad range of products, both developed itself and in-licensed from third parties. AFT's products cover all major pharmaceutical distribution channels: over-the-counter, prescription and hospital. Historically, AFT's home markets have been Australia, New Zealand and South-East Asia. However, the company is out-licensing its own products to licensees and distributors to sell in an increasing number of countries around the world. The company's intensive Research and Development program forms the basis of its international sales strategy. For more information about the company, visit our website www.aftpharm.com.

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand

Incorporated in New Zealand ARBN: ARBN 609 017 969 investor.relations@aftpharm.com

This is an excerpt of the original content. To continue reading it, access the original document here.


AFT Pharmaceuticals Limited published this content on 11 January 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 January 2021 05:09:00 UTC

© Publicnow 2021
04/13SHINTR : AFT: D&O Ongoing Disclosure - Louise ClaytonOpens in a new Window
04/13SHINTR : AFT: D&O Ongoing Disclosure - Malcolm TubbOpens in a new Window
04/13SECISSUE : AFT: Capital Change Notice - Issue of ordinary sharesOpens in a new W..
04/12AFT Pharma's Hand Sanitizer Set for Distribution in Middle East, Africa
04/11AFT PHARMACEUTICALS  : Crystawash Extend distribution in UAE, Kuwait, Oman and K..
04/06AFT PHARMACEUTICALS  : Partners With Poland's Mercapharm and Greece's Vianex for..
04/06GENERAL : AFT: AFT secures new partners in Poland and Greece Opens in a new Wind..
04/01AFT PHARMACEUTICALS  : Lowers Fiscal 2021 Operating Profit Guidance
04/01AFT PHARMACEUTICALS  : Lowers Earnings Guidance for Fiscal 2021 Due to Licensing..
03/31GENERAL : AFT: AFT updates earnings guidanceOpens in a new Window
More news
Sales 2021 110 M 79,5 M 79,5 M
Net income 2021 7,79 M 5,62 M 5,62 M
Net Debt 2021 31,8 M 22,9 M 22,9 M
P/E ratio 2021 55,1x
Yield 2021 -
Capitalization 429 M 308 M 309 M
EV / Sales 2021 4,18x
EV / Sales 2022 3,47x
Nbr of Employees 86
Free-Float 28,2%
Duration : Period :
AFT Pharmaceuticals Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AFT PHARMACEUTICALS LIMITED
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 3
Average target price 4,61 NZD
Last Close Price 4,10 NZD
Spread / Highest target 19,5%
Spread / Average Target 12,3%
Spread / Lowest Target 5,12%
EPS Revisions
Managers and Directors
Hartley Atkinson Chief Executive Officer, MD & Executive Director
Malcolm Tubby Chief Financial Officer & Secretary
David Mark Flacks Chairman
Douglas John Wilson Independent Non-Executive Director
Jon Lamb Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON3.37%427 130
ROCHE HOLDING AG0.06%289 376
PFIZER, INC.4.78%215 150
NOVARTIS AG-3.32%198 528
MERCK & CO., INC.-5.06%196 100